 SAN DIEGO, July 06, 2021 GLOBE NEWSWIRE -- Sorrento Therapeutics, Inc. NASDAQ: SRNE, Sorrento announced today that the company has received FDA clearance to proceed with a Phase 2 clinical study of RTX for treating moderate-to-severe osteoarthritis of the knee pain OAK. 